Nonadherence in Tuberculosis Treatment: Predictors and Consequences in New York City


      BACKGROUND: Poor adherence to antituberculosis treatment is the most important obstacle to tuberculosis control.
      PURPOSE: To identify and analyze predictors and consequences of nonadherence to antituberculosis treatment.
      PATIENTS AND METHODS: Retrospective study of a citywide cohort of 184 patients with tuberculosis in New York City, newly diagnosed by culture in April 1991—before the strengthening of its control program—and followed up through 1994. Follow-up information was collected through the New York City tuberculosis registry. Nonadherence was defined as treatment default for at least 2 months.
      RESULTS: Eighty-eight of the 184 (48%) patients were nonadherent. Greater nonadherence was noted among blacks (unadjusted relative risk [RR] 3.0, 95% confidence interval [CI] 1.1 to 8.6, compared with whites), injection drug users (RR 1.5, 95% CI 1.1 to 2.0), homeless (RR 1.4, 95% CI 1.0 to 1.8), alcoholics (RR 1.4, 95% CI 1.0 to 1.9), and HIV-infected patients (RR 1.4, 95% CI 1.1 to 1.9); also, census-derived estimates of household income were lower among nonadherent patients (P = 0.018). In multivariate analysis, only injection drug use and homelessness predicted nonadherence, yet 46 (39%) of 117 patients who were neither homeless nor drug users were nonadherent. Nonadherent patients took longer to convert to negative culture (254 versus 64 days, P <0.001), were more likely to acquire drug resistance (RR 5.6, 95% CI 0.7 to 44.2), required longer treatment regimens (560 versus 324 days, P <0.0001), and were less likely to complete treatment (RR 0.5, 95% CI 0.4 to 0.7). There was no association between treatment adherence and all-cause mortality.
      CONCLUSIONS: In the absence of public health intervention, half the patients defaulted treatment for 2 months or longer. Although common among the homeless and injection drug users, the problem occurred frequently and unpredictably in other patients. Nonadherence may contribute to the spread of tuberculosis and the emergence of drug resistance, and may increase the cost of treatment. These data lend support to directly observed therapy in tuberculosis.
      To read this article in full you will need to make a payment


        • Raviglione MC
        • Snider DE
        • Kochi A
        Global epidemiology of tuberculosis: morbidity and mortality of a worldwide epidemic.
        JAMA. 1995; 273: 220-226
        • Bloch AB
        • Reider HL
        • Kelly GD
        • et al.
        The epidemiology of tuberculosis in the United States: implications for diagnosis and treatment.
        Clin Chest Med. 1989; 10: 297-313
        • Jereb JA
        • Kelly GD
        • Dooley SW
        • et al.
        Tuberculosis morbidity in the United States: final data, 1990.
        MMWR. 1992; 40: 23-27
        • Centers for Disease Control
        Tuberculosis Statistics: States and Cities, 1985. DHHS publication no 87-8249.
        Washington Printing Office, Washington, DC1986
        • New York City Department of Health
        Tuberculosis in New York City, 1990: Information Survey.
        New York City Department of Health, New York1991
        • Barnes PF
        • Barrows SA
        Tuberculosis in the 1990's.
        Ann Intern Med. 1993; 119: 400-410
        • Drucker E
        • Alcabes P
        • Bosworth W
        • Sckell B
        Childhood tuberculosis in the Bronx, New York.
        Lancet. 1994; 343: 1482-1485
        • Cantwell MF
        • Snider DE
        • Cauthen GM
        • Onorato IM
        Epidemiology of tuberculosis in the United States, 1985 through 1992.
        JAMA. 1994; 272: 535-539
        • Brudney K
        • Dobkin J
        A tale of two cities: tuberculosis control in Nicaragua and New York City.
        Sem Respir Infect. 1991; 6: 261-272
        • Brudney K
        • Dobkin J
        Resurgent tuberculosis in New York City: human immunodeficiency virus, homelessness, and the decline of tuberculosis control programs.
        Am Rev Respir Dis. 1991; 144: 745-749
        • Fox W
        The problem of self-administration of drugs, with particular reference to pulmonary tuberculosis.
        Tubercle. 1958; 39: 269-274
        • Tuberculosis chemotherapy centre, Madras
        A concurrent comparison of intermittent (twice weekly) isoniazid plus streptomycin and daily isoniazid plus PAS in the domiciliary treatment of pulmonary tuberculosis.
        Bull WHO. 1964; 31: 247-271
        • Moodie AS
        Mass ambulatory chemotherapy in the treatment of tuberculosis in a predominantly urban community.
        Am Rev Respir Dis. 1967; 95: 384-397
        • Moulding T
        New responsibilities for health departments and public health nurses in tuberculosis: keeping the outpatient on therapy.
        Am J Pub Health. 1966; 56: 416-427
        • Bayer R
        • Wilkinson D
        Directly observed therapy: history of an idea.
        Lancet. 1995; 345: 1545-1548
        • Frieden TR
        • Sterling T
        • Pablos-Méndez A
        • et al.
        The emergence of drug-resistant tuberculosis in New York City.
        NEJM. 1993; 328: 521-526
        • Bloch AB
        • Cauthen GM
        • Onorato IM
        • et al.
        Nationwide survey of drug-resistant tuberculosis in the United States.
        JAMA. 1994; 271: 665-671
        • Bifani PJ
        • Plikaytis BB
        • Kapur V
        • et al.
        Origin and interstate spread of a New York City multidrug-resistant Mycibacterium tuberculosis lone family.
        JAMA. 1996; 275: 452-457
        • Addington WW
        Patient compliance: the most serious remaining problem in control of tuberculosis in the US.
        Chest. 1979; 76: 741-743
        • Ferrer X
        • Kirschbaum A
        • Toro J
        • et al.
        Compliance with tuberculosis treatment in adults in Santiago, Chile.
        Boletín de la Oficina Sanitaria Panamericana. 1991; 111: 423-431
        • Crespo R
        • Valdes L
        • Bobe I
        • Cayla JA
        Difficulties in carrying out the treatment as seen by the tuberculous patient.
        Atención Primaria. 1992; 9: 260-262
        • Sumartojo E
        When tuberculosis treatment fails.
        Am Rev Respir Dis. 1993; 147: 1311-1320
        • Ormerod LP
        • Prescott RJ
        Inter-relations between relapses, drug regimens and compliance with treatment in tuberculosis.
        Respir Med. 1991; 85: 239-242
        • WHO Tuberculosis Programme
        Framework for Effective Tuberculosis Control.
        WHO/TB/94, Geneva, Switzerland1994
        • Stampfer MJ
        • Willet WC
        • Speizer FE
        Test of the national death index.
        Am J Epidemiol. 1984; 119: 837-839
      1. Dean AG, Dean JA, Coulombier D, et al. Epi Info, Version 6. Atlanta, Georgia: Centers for Disease Control and Prevention; and Geneva, Switzerland: World Health Organization; 1994.

        • Norusis MJ
        SPSS for Windows: Advanced Statistics, Release 6.0.
        SPSS Inc, Chicago, Illinois1993
        • Hosmer DW
        • Lemeshow SL
        Applied Logistic Regression.
        Wiley & Sons, New York1989
        • Pablos-Méndez A
        • Sterling TR
        • Frieden TR
        The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis.
        JAMA. 1996; 276: 1223-1228
        • Kim SJ
        • Hong YP
        Drug resistance of Mycobacterium tuberculosis in Korea.
        Tuber Lung Dis. 1992; 73: 219-224
        • Weis SE
        • Slocum PC
        • Blais FX
        • et al.
        The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis.
        NEJM. 1994; 330: 1179-1184
        • Melnikow J
        • Kiefe C
        Patient compliance and medical research: issues in methodology.
        J Gen Intern Med. 1994; 9: 96-105
        • Krieger N
        Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology.
        Am J Pub Health. 1992; 92: 703-710
      2. Haynes RB Taylor DW Sackett DL Compliance in Health Care. Johns Hopkins University Press, Baltimore, Maryland1979
        • Stephenson BJ
        • Rowe BH
        • Haynes RB
        • et al.
        Is this patient taking the treatment as prescribed?.
        JAMA. 1993; 269: 2779-2781
        • Mahmoudi A
        • Iseman MD
        Pitfalls in the care of patients with tuberculosis.
        JAMA. 1993; 270: 65-68
        • Morisky DE
        • Malotte CK
        • Choi P
        • et al.
        A patient education program to improve adherence rates with antituberculosis drug regimens.
        Health Educ Q. 1990; 17: 253-267
        • Barnwell MD
        • Chitkara R
        • Lamberta F
        Tuberculosis prevention project.
        J Natl Med Assoc. 1992; 84: 1014-1018
        • Frieden TR
        • Fujiwara PI
        • Washko RM
        • Hamburg MA
        Tuberculosis in New York City—turning the tide.
        NEJM. 1995; 333: 229-233
        • China Tuberculosis Control Collaboration
        Results of directly observed short course chemotherapy in 112,842 Chinese patients with smear-positive tuberculosis.
        Lancet. 1996; 347: 358-362
      3. Approaches to improving adherence to antituberculosis therapy—South Carolina and New York, 1986 1991. MMWR. 1993;42:74–75.

        • Centers for Disease Control and Prevention
        Tuberculosis control laws—United States, 1993: recommendations of the Advisory Council for the Elimination of Tuberculosis (ACET).
        MMWR. 1993; 42: 1-13
        • Chaulk CP
        • Moore-Rice K
        • Rizzo R
        • Chaisson RE
        Eleven years of community-based directly observed therapy for tuberculosis.
        JAMA. 1995; 274: 945-951
        • Iseman MD
        • Cohn DL
        • Sbarbaro JA
        Directly observed treatment of tuberculosis. We can't afford not to do it.
        NEJM. 1993; 328: 576-578
        • Murray CJ
        • Styblo K
        • Rouillon A
        Tuberculosis in developing countries: burden, intervention and cost.
        Bull IUATLD. 1990; 65: 6-64
        • Division of Tuberculosis Elimination, National Center for HIV, STD and TB Prevention (proposed), CDC
        Tuberculosis morbidity—United States, 1995.
        MMWR. 1996; 45: 365-370
        • Dubler NN
        • et al.
        Tuberculosis in the 1990s: ethical, legal, and public policy issues in screening, treatment, and the protection of those in congregate facilities.
        in: The Tuberculosis Revival—Individual Rights and Societal Obligation in a Time of AIDS. United Hospital Fund, New York1992: 1-21
        • American Thoracic Society
        Treatment of tuberculosis and tuberculosis infection in adults and children.
        Am J Respir Crit Care Med. 1994; 149: 1359-1374
        • Annas GJ
        Control of tuberculosis: the law and the public health.
        NEJM. 1993; 328: 585-588
        • Gostin L
        Controlling the re-emergent tuberculosis epidemic: a fifty-state survey of TB statues and proposals for reform.
        JAMA. 1993; 269: 255-261
        • Lerner BH
        Temporarily detained: tuberculous alcoholics in Seattle, 1949 through 1960.
        Am J Pub Health. 1996; 86: 257-265